On January 5, 2026, Skye Bioscience Inc. and Halozyme Therapeutics Inc. announced a global non-exclusive collaboration and licensing agreement to advance drug delivery capabilities.
Focus of the partnership Skye Bioscience will utilize Halozyme’s ENHANZE technology to develop a subcutaneous formulation of nimacimab, an investigational therapy for obesity. The collaboration aims to:
-
Enable higher dosing: The technology facilitates the subcutaneous delivery of larger injection volumes, allowing Skye to evaluate the efficacy of increased nimacimab doses.
-
Support combination strategies: This approach provides a validated method to test nimacimab both as a monotherapy and in combination with GLP-1 receptor agonists.
Financial terms and obligations Under the agreement, Skye will make milestone payments to Halozyme upon reaching specific development and commercial goals. Additionally, Halozyme is entitled to mid-single-digit royalties on net sales of the co-formulated product for at least a 10-year period.
Clinical milestones Skye Bioscience plans to launch a Phase 2b clinical trial in mid-2026 to evaluate nimacimab integrated with the ENHANZE technology. This study will represent a significant step in assessing the drug’s potential within the rapidly expanding obesity therapeutic market.